2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Alpelisib 300 mg: new trials by email Literature Review of Alpelisib 300 mg trials Research Report on Alpelisib 300 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alpelisib Challenge Test (ACT) Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp - Insulin Resistance, Type 2 Diabetes | Phase 1 | Recruiting | Columbia University | 15 | 2026-09-02 | 2026-09-03 |
| Human Models of Selective Insulin Resistance: Alpelisib, Part I Alpelisib 300 mg, Placebo, [1-13C] sodium acetate - Insulin Resistance, Prediabetic State | Phase 1 | Recruiting | Columbia University | 32 | 2024-04-24 | 2026-08-24 |
Hyperinsulinism (2) · Insulin Resistance (2) · Obesity (2) · Overweight (2) · Diabetes Mellitus, Type 2 (1) · Fatty Liver (1) · Non-alcoholic Fatty Liver Disease (1) · Prediabetic State (1)
United States (2)
K23DK140614 (2), K12DK133995 (1)